Insmed To Present at March 2026 Investor Conferences
Rhea-AI Summary
Insmed (Nasdaq: INSM) announced management will present at two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference on March 2, 2026 at 9:50 a.m. ET and the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
Both presentations will be webcast live and archived for 30 days on the company investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – INSM
In the Feb 13 session, INSM gained 1.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings call scheduling | Neutral | -0.9% | Announced Q4 and full-year 2025 results call with business update. |
| Jan 28 | Clinical presentations | Positive | -4.2% | Multiple TPIP abstracts at PVRI 2026, including Phase 3 design and Phase 2b data. |
| Jan 09 | Business update | Positive | +3.4% | Strong 2025 revenue, BRINSUPRI launch progress, and key ENCORE/CEDAR timelines. |
| Jan 02 | Conference appearance | Neutral | +1.8% | Planned presentation at J.P. Morgan Healthcare Conference with webcast access. |
| Dec 17 | Clinical update | Negative | -1.1% | BiRCh Phase 2b CRSsNP study missed endpoints; program discontinued, new asset added. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News-driven moves have mostly aligned with the tone of prior updates, with one notable sell-off following positive TPIP abstract presentations.
Over the past few months, Insmed has combined clinical, commercial, and investor-relations catalysts. A January business update highlighted strong 2025 net product revenue of $606.4M and outlined 2026 revenue expectations and key readout timelines. Other updates included clinical results, a discontinued CRSsNP program, and multiple conference and earnings call announcements. The current notice of March 2026 investor conferences fits the pattern of regular engagement with the healthcare investment community following significant business and clinical milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 46th Annual TD Cowen Healthcare Conference in
Boston , on Monday, March 2, 2026, at 9:50 a.m. ET. - Leerink Partners Global Healthcare Conference in
Miami , on Tuesday, March 10, 2026, at 8:00 a.m. ET.
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-march-2026-investor-conferences-302682778.html
SOURCE Insmed Incorporated